Filing Flows › Co-Diagnostics (CODX) › Q2 2026 › vs Q2 2025
Co-Diagnostics (CODX) Q2 2026 vs Q2 2025 (year over year)
Co-Diagnostics's revenue rose $3K (+2%) from $163K in Q2 2025 to $166K in Q2 2026.
Co-Diagnostics, Q2 2026: revenue $166K (+2% year over year), net loss $6.3M, operating cash flow −$7.2M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $166K | $163K | $3K | +2% |
| Net loss | $6.3M | $7.7M | −$1.4M | -19% |
| Costs & expenses | $6.4M | $8.2M | −$1.8M | -22% |
| Operating costs | $6.4M | $8.2M | −$1.9M | -23% |
| Interest & other, net | $64K | −$340K | $404K | — |
| Income tax | $19K | $12K | $7K | +55% |
| Cost of revenue | $45K | $32K | $13K | +41% |
| Research & development | $4.2M | $4.7M | −$535K | -11% |
| Sales & marketing | $467K | $610K | −$143K | -23% |
| General & admin | $1.5M | $2.6M | −$1.1M | -42% |
| Other operating costs | $202K | $291K | −$90K | -31% |
| Operating cash sources | $7.6M | $9.2M | −$1.6M | -17% |
| Depreciation & amortization | $202K | $291K | −$90K | -31% |
| Share-based compensation | $214K | $580K | −$367K | -63% |
| Cash used in operations | $7.2M | $8.3M | −$1.1M | -14% |
| Net loss absorbed | $6.3M | $7.7M | −$1.4M | -19% |
| Working capital & other | $1.3M | $1.4M | −$145K | -10% |
Questions
How much did Co-Diagnostics's revenue grow year over year in Q2 2026?
Co-Diagnostics's revenue rose $3K (+2%) from $163K in Q2 2025 to $166K in Q2 2026.